Regeneron Pharmaceuticals, Inc.

Other

Christopher Daly

Gavin Thurston

Douglas MacDonald

Xunbao Duan

Thomas Nittoli

Nicholas J Papadopoulos

Israel Lowy

Frank Delfino

Amy Han

William C Olson

Gang Chen

Samuel H Davis

Robert Babb

Julian Andreev

Li Zhang

Lisa Purcell Ngambo

John DaSilva

Andres Perez Bay

Tara Young

Provided herein are methods and compositions related to the treatment or prevention of cancer (e.g., by targeting a tumor in a subject with cancer) by administering to a subject an agent that inhibits autophagy. In certain aspects, provided herein are methods of compositions related to methods of sensitizing cancer cells to tumor necrosis factor-alpha (TNF-α) mediated killing by contacting the cells or administering the agent that inhibits autophagy.

Methods and compositions for sensitization of tumor cells to immune therapy

Provided herein are bispecific antigen-binding molecules that bind HER2 and methods of use thereof. The bispecific antigen-binding molecules comprise a first and a second antigen-binding domain, wherein the first and second antigen-binding domains bind to two different (preferably non-overlapping) epitopes of the extracellular domain of human HER2. The bispecific antigen-binding molecules cluster on the surface of HER2 IHC2+ and IHC3+ cells, and are internalized into the cellular lysosomes. Also included are antibody-drug conjugates (ADCs) comprising the antibodies or bispecific antigen-binding molecules provided herein linked to a cytotoxic agent, radionuclide, or other moiety, as well as methods of treating cancer in a subject by administering to the subject a bispecific antigen-binding molecule or an ADC thereof.

Bispecific antigen binding molecules that bind HER2, and methods of use thereof

Provided herein are monoclonal antibodies, and antigen-binding fragments thereof, that bind fibroblast growth factor receptor 2 (FGFR2), and methods of use thereof and methods of use thereof. Also included are antibody-drug conjugates (ADCs) comprising the anti-FGFR2 antibodies or antigen-binding fragments thereof linked to a cytotoxic agent, radionuclide, or other moiety, as well as methods of treatment using the same.

Anti-FGFR2 antibodies and methods of use thereof

The present invention provides antibodies that bind to ErbB3 and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human ErbB3. In certain embodiments, the antibodies of the present invention block the interaction of ErbB3 with an ErbB3 ligand such as neuregulin 1. The antibodies of the invention are useful for the treatment of various cancers.

Anti-ErbB3 antibodies and uses thereof

Provided herein are antibodies and bispecific antigen-binding molecules that bind MET and methods of use thereof. The bispecific antigen-binding molecules comprise a first and a second antigen-binding domain, wherein the first and second antigen-binding domains bind to two different (preferably non-overlapping) epitopes of the extracellular domain of human MET. The bispecific antigen-binding molecules are capable of blocking the interaction between human MET and its ligand HGF. The bispecific antigen-binding molecules can exhibit minimal or no MET agonist activity, e.g., as compared to monovalent antigen-binding molecules that comprise only one of the antigen-binding domains of the bispecific molecule, which tend to exert unwanted MET agonist activity. Also included are antibody-drug conjugates (ADCs) comprising the antibodies or bispecific antigen-binding molecules provided herein linked to a cytotoxic agent, radionuclide, or other moiety, as well as methods of treating cancer in a subject by administering to the subject a bispecific antigen-binding molecule or an ADC thereof.

Anti-MET antibodies, bispecific antigen binding molecules that bind MET, and methods of use thereof

The present invention provides antibodies that bind to angiopoietin-2 (Ang-2) and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human Ang-2. The antibodies of the invention are useful, inter alia, for the treatment of diseases and disorders associated with one or more Ang-2 biological activities including angiogenesis.

High affinity human antibodies to human angiopoietin-2

The present invention provides methods for promoting blood coagulation and/or treating blood coagulation disorders in a subject in need thereof. The methods of the present invention comprise administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising an angiopoietin protein or a modified angiopoietin protein molecule such as AngF1-Fc-F1 or AngF2-Fc-F2.

Use of angiopoietins in promoting blood coagulation and in the treatment of blood coagulation disorders

Method for treating an eye disease or disorder by administering an antibody that binds angiopoietin-2

Methods for treating hepatocellular cancer by administering an anti-Ang-2 antibody

The present invention provides antibodies that bind to EGFR and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human EGFR with high affinity. In certain embodiments, the antibodies of the present invention are capable of inhibiting the growth of tumor cells expressing high levels of EGFR and/or inducing antibody-dependent cell-mediated cytotoxicity (ADCC) of such cells. The antibodies of the invention are useful for the treatment of various cancers as well as other EGFR-related disorders.

Anti-EGFR antibodies and uses thereof

The present invention provides methods for treating malaria by administering to a patient in need thereof a pharmaceutical composition comprising an antibody that specifically binds human angiopoietin-2 (Ang-2).

Methods for treating malaria by administering an antibody that specifically binds angiopoietin-2 (ang-2)

The present invention provides pharmaceutical compositions comprising an anti-ErbB3 antibody and an anti-EGFR antibody, and methods of use thereof. The compositions and methods of the present invention are useful for the treatment of various cancers and other diseases and disorders.

Growing community of inventors

New York, NY, United States of America

Christopher Daly